you are viewing a single comment's thread.
The FDA is having issues granting NCE because Vascepa is the active ingredient in Lovaza. AMRN does qualify for 3 year exclusivity, as NME, but no NCE. This will drag on the stock price.
Hello???? A delay would ONLY mean NCE approval is coming. If NCE was going to be denied no delay would be needed. Simple logic here guys.
If you are correct, it will drag on the pps short-term, but not long-term. This is a monster in the making. Now if we can just find enough algae for the fish to eat to get the epa